Table 3.
Clinical and Cognitive Outcomes of the Subset of Participants with Follow-up (n = 54)a
| Baseline | Follow-up | p-value | |
|---|---|---|---|
| CD4+ T-lymphocyte (cells/μL) | 248 (46–355) | 468 (261–673) | < 0.001 |
| On cART with CPE > 7, n (%) | – | 7 (13) | – |
| HIV-1 RNA suppressionb, n (%) | – | 46 (85) | – |
| IHDS score | 10 (10–11) | 11 (10–12) | < 0.001 |
| IHDS ≤10, n (%) | 31 (57) | 17 (32) | < 0.001 |
| MoCA score | 27 (26–29) | 27 (26–28) | 0.818 |
| MoCA ≤25, n (%) | 13 (24) | 12 (22) | 1.000 |
| MoCA ≤21, n (%) | 4 (7) | 4 (7) | 1.000 |
Median (IQR) is presented unless specified otherwise
aOnly included participants who were on cART
bBlood HIV-1 RNA level < 20 copies/mL
Abbreviations: IHDS International HIV Dementia Scale, MoCA Montreal Cognitive Assessment, CPE CNS penetration-effectiveness